These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24656569)

  • 1. Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor.
    Han AL; Kumar S; Fok JY; Tyagi AK; Mehta K
    Eur J Cancer; 2014 Jun; 50(9):1685-96. PubMed ID: 24656569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
    Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    Morel KL; Hamid AA; Clohessy JG; Pandell N; Ellis L; Sweeney CJ
    Mol Cancer Res; 2021 Jul; 19(7):1137-1145. PubMed ID: 33863813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.
    Ko S; Shi L; Kim S; Song CS; Chatterjee B
    Mol Endocrinol; 2008 Feb; 22(2):273-86. PubMed ID: 17975021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
    Kumar A; Xu J; Sung B; Kumar S; Yu D; Aggarwal BB; Mehta K
    Breast Cancer Res; 2012 Jan; 14(1):R4. PubMed ID: 22225906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.
    Deng C; Chen J; Guo S; Wang Y; Zhou Q; Li Z; Yang X; Yu X; Zhang Z; Zhou F; Han H; Yao K
    World J Urol; 2017 Aug; 35(8):1213-1221. PubMed ID: 28105499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression.
    Ai L; Skehan RR; Saydi J; Lin T; Brown KD
    J Biol Chem; 2012 May; 287(22):18330-41. PubMed ID: 22493284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.
    Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW
    Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation of transglutaminase 2 (TG2) at serine-216 has a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of PTEN.
    Wang Y; Ande SR; Mishra S
    BMC Cancer; 2012 Jul; 12():277. PubMed ID: 22759359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical pathway.
    Kumar S; Mehta K
    PLoS One; 2012; 7(11):e49321. PubMed ID: 23185316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase C regulates Twist1 expression via NF-κB in prostate cancer.
    Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Eto M
    Endocr Relat Cancer; 2017 Apr; 24(4):171-180. PubMed ID: 28223364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
    Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
    PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
    Kumar S; Donti TR; Agnihotri N; Mehta K
    Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.
    Lin CY; Tsai PH; Kandaswami CC; Chang GD; Cheng CH; Huang CJ; Lee PP; Hwang JJ; Lee MT
    Mol Cancer; 2011 Jul; 10():87. PubMed ID: 21777419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype.
    Brown KD
    Breast Cancer Res Treat; 2013 Jan; 137(2):329-36. PubMed ID: 23224146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway.
    Mann AP; Verma A; Sethi G; Manavathi B; Wang H; Fok JY; Kunnumakkara AB; Kumar R; Aggarwal BB; Mehta K
    Cancer Res; 2006 Sep; 66(17):8788-95. PubMed ID: 16951195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.
    Bluemn EG; Spencer ES; Mecham B; Gordon RR; Coleman I; Lewinshtein D; Mostaghel E; Zhang X; Annis J; Grandori C; Porter C; Nelson PS
    Mol Cancer Res; 2013 Jun; 11(6):568-78. PubMed ID: 23493267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines.
    Atobatele AG; Tonoli E; Vadakekolathu J; Savoca MP; Barr M; Kataria Y; Rossanese M; Burhan I; McArdle S; Caccamo D; Verderio EAM
    Cell Death Dis; 2023 May; 14(5):317. PubMed ID: 37160910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.